Analysts have been expressing mixed sentiments towards Mirum Pharmaceuticals (NASDAQ: MIRM) in the past quarter, with opinions ranging from optimistic to cautious. Here is a breakdown of the recent analyst ratings and price targets:
Rating Breakdown:
Bullish: 2
Somewhat Bullish: 2
Indifferent: 0
Somewhat Bearish: 0
Bearish: 0
Recent Changes:
In the Last 30 Days:
Bullish: 0
Somewhat Bullish: 1
1 Month Ago: No changes
2 Months Ago:
Somewhat Bullish: 1
3 Months Ago:
Bullish: 2
Price Targets:
Average Target: $55.25
High Estimate: $64.00
Low Estimate: $35.00
Change from Previous Average Target: Decrease of 19.93%
Recent Analyst Actions and Ratings:
– Josh Schimmer from Cantor Fitzgerald maintains an “Overweight” rating with a price target of $35.00.
– Jonathan Wolleben at JMP Securities maintains a “Market Outperform” rating with a price target of $64.00.
– Steven Seedhouse from Raymond James lowered the rating to “Strong Buy” with a price target of $64.00 (previously $78.00).
– Ed Arce at HC Wainwright & Co. lowered the rating to “Buy” with a price target of $58.00 (previously $60.00).
Analysts are constantly adjusting their recommendations in response to market dynamics and company performance, reflecting their reactions to recent developments concerning Mirum Pharmaceuticals.
Date: February 29, 2024.
MIRM Stock Price Update: February 29, 2024 – Slight Decrease in Price Momentum
On February 29, 2024, MIRM stock experienced a slight decrease in price momentum. The stock opened at $28.59, which was $0.30 lower than its previous close. Throughout the trading day, the price of MIRM shares dropped by $0.25, representing a 0.87% decrease from the previous market close. Despite the drop in price on this particular day, MIRM is still trading above its 200-day simple moving average. Investors should continue to monitor MIRM’s performance in the coming days and weeks to see if the stock can regain its momentum and potentially move higher.
MIRM Stock Analysis: Strong Revenue Growth Despite Net Loss – February 29, 2024
On February 29, 2024, MIRM stock showed some interesting performances based on the financial data provided by CNN Money. The company’s total revenue for the past year was $77.06 million, which represented a significant increase of 302.66% compared to the previous year. In the third quarter alone, MIRM reported a total revenue of $47.73 million, showing a 27.28% increase since the previous quarter.
However, despite the impressive revenue growth, MIRM’s net income figures tell a different story. The company reported a net loss of $135.66 million for the past year, which marked a 61.53% decrease compared to the previous year. In the third quarter, MIRM’s net loss improved to $23.59 million, showing a 68.14% increase since the previous quarter.
Earnings per share (EPS) also showed mixed results for MIRM stock on February 29, 2024. The company reported an EPS of -$4.02 for the past year, reflecting a 45.1% decrease compared to the previous year. However, in the third quarter, MIRM’s EPS improved to -$0.57, showing a significant increase of 70.46% since the previous quarter.
Overall, MIRM stock exhibited a combination of strong revenue growth and improving net income and EPS figures. Investors may view the company’s revenue growth positively, but the net income and EPS figures may raise some concerns about the company’s profitability and financial health. It will be interesting to see how MIRM stock performs in the coming months as investors continue to monitor the company’s financial performance and market dynamics.
